Vibha Ravi
Senior Editor, Citeline - Scrip, Pink Sheet. Tweets on pharma, health, environment, other topics of interest to those who read beyond headlines, social media
Articles
-
6 days ago |
insights.citeline.com | Lisa Takagi |Joseph Haas |Anju Ghangurde |Vibha Ravi
Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding PlatformPlus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.
-
2 weeks ago |
insights.citeline.com | Vibha Ravi
Pipeline To Product – What Is Driving Cell And Gene Therapy Progress In India? US-based Colossal Labs has claimed to bring back the dire wolf from extinction. While the science is not as dramatic in India yet, cell and gene therapies are making progress as treatments for cancer and other diseases. Pink Sheet takes a look at what is driving CGT success and growth Cell And Gene Therapy Is Picking Up Pace In India (Shutterstock)
-
2 weeks ago |
insights.citeline.com | Vibha Ravi
What Is Fuelling Cell And Gene Therapies In India? Bharat Biotech is the latest entrant in India’s cell and gene therapy (CGT) space, joining majors like Intas Pharma, Sun Pharma, Cipla and Dr. Reddy’s. An indigenously developed CAR-T cell therapy launched last year, what is driving growing interest and success in cell and gene therapies? Cell And Gene Therapy Is Picking Up Pace In India (Shutterstock)
-
3 weeks ago |
insights.citeline.com | Vibha Ravi
Trump Tariffs: Indian Pharma Dodges Bullet, But Sword May RemainQuestion About Costs For Firms With US Manufacturing Trump announced a 26% reciprocal tariff on India, but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying? US tariffs are raising economic concerns around the world. (Shutterstock)
-
3 weeks ago |
insights.citeline.com | Vibha Ravi
Trump Tariffs – Indian Pharma Dodges Bullet, But Sword Still Hangs? Trump announced a 26% reciprocal tariff on India but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms and the US consumer are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying? US Tariffs Are Causing A Flutter Across The World (Shutterstock)
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 673
- Tweets
- 4K
- DMs Open
- Yes
Tariffs on US drug imports could still come, but 90 day tariff pause for most global trade partners suggests they won’t be immediate #Tariffs #TradeWar #Trump #WhiteHouse #pharmaceuticals https://t.co/OzpoITY5K6
Trump: 90 day pause for higher US reciprocal tariffs, but 10% applies to most nations during this time. Pharma tariffs intended. Hits China with 125% as White House warns 'don't reciprocate' #Tariffs #TradeWar #US #BusinessNews #pharmaceuticalsPresident https://t.co/IvA7bFXiQX
Makary Pledges To Uphold Gold Standard Science, But First Address Confuses Some US FDA Staff. By @dgingery @SarahKarlin #FDA #Regulation #Biotechnology https://t.co/0DSiOgji3b